Crossmark

Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas

Crossref DOI link: https://doi.org/10.1007/s00280-021-04274-6

Published Online: 2021-04-26

Published Print: 2021-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schalkwijk, Stein https://orcid.org/0000-0001-8204-5242
Zhou, Li

Cohen‐Rabbie, Sarit

Jain, Lokesh

Freshwater, Tomoko

So, Karen

He, Zhongqing

Gioni, Ioanna

Tomkinson, Helen

Vishwanathan, Karthick

Zhou, Diansong
Funding

Funding for this research was provided by:

AstraZeneca
License Information

Text and Data Mining valid from 2021-04-26

Version of Record valid from 2021-04-26
More Information

Article History

Received: 27 November 2020

Accepted: 3 April 2021

First Online: 26 April 2021

Declarations:

:

: SS, KS, HT, KV and DZ are employees of AstraZeneca, and own stock options/shares. SC, IG and ZH are employees of AstraZeneca. TF and LJ are employees of Merck & Co., Inc., and owns stock options/shares. LZ is a former employee of AstraZeneca and a current employee of Pfizer.

: As this is a pooled study based on existing data, ethics approvals for this study are not applicable.

: As this is a pooled study based on existing data, consent for this study is not applicable.

Document is current

Any future updates will be listed below